investorscraft@gmail.com

Adverum Biotechnologies, Inc. (ADVM)

Previous Close
$2.28
Sector Valuation Confidence Level
High
Valuation methodValue, $Upside, %
Artificial intelligence (AI)432.8718886
Intrinsic value (DCF)0.00-100
Graham-Dodd Methodn/a
Graham Formula403.2717587

Company Information

800 Saginaw Drive
Redwood City, CA 94063
United States
Phone: 650 656 9323
Industry: Biotechnology
Sector: Healthcare
CEO: Dr. Laurent Fischer
Full Time Employees: 155

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

HomeMenuAccount